Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers.

Autor:	Loi P; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Schade AE; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Rodriguez CL; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Krishnan A; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Perurena N; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Nguyen VTM; Division of Cancer Biology, The Institute of Cancer Research, London, United Kingdom., Xu Y; Ludwig Center at Harvard, Boston, Massachusetts.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Watanabe M; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Davis RA; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Gardner A; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Pilla NF; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Mattioli K; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Popow O; Harvard Medical School, Boston, Massachusetts.; Dana Farber Institute, Boston, Massachusetts., Gunduz N; CRUK Beatson Institute, Glasgow, United Kingdom.; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Lannagan TRM; CRUK Beatson Institute, Glasgow, United Kingdom.; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Fitzgerald S; Harvard Medical School, Boston, Massachusetts.; Dana Farber Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Sicinska ET; Dana Farber Institute, Boston, Massachusetts., Lin JR; Ludwig Center at Harvard, Boston, Massachusetts.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Tan W; Dana Farber Institute, Boston, Massachusetts., Brais LK; Dana Farber Institute, Boston, Massachusetts., Haigis KM; Harvard Medical School, Boston, Massachusetts.; Dana Farber Institute, Boston, Massachusetts., Giannakis M; Harvard Medical School, Boston, Massachusetts.; Dana Farber Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Ng K; Dana Farber Institute, Boston, Massachusetts., Santagata S; Ludwig Center at Harvard, Boston, Massachusetts.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Helin K; Division of Cancer Biology, The Institute of Cancer Research, London, United Kingdom., Sansom OJ; CRUK Beatson Institute, Glasgow, United Kingdom.; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Cichowski K; Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Ludwig Center at Harvard, Boston, Massachusetts.
Jazyk:	angličtina
Zdroj:	Cancer discovery [Cancer Discov] 2024 Dec 02; Vol. 14 (12), pp. 2430-2449.
DOI:	10.1158/2159-8290.CD-23-0866
Abstrakt:	Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells. (©2024 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu